BofA analyst Adam Ron lowered the firm’s price target on Astrana Health (ASTH) to $49 from $55 and keeps a Buy rating on the shares after the company reported “somewhat mixed” Q4 results. Elevated medical loss ratio pressure and a “disappointing outlook” lowers the firm’s confidence moderately and it reduced its forward estimates, the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health Updates Corporate Presentation for Conferences
- Astrana Health price target lowered to $50 from $86 at Baird
- Astrana Health’s Earnings Call: Growth Amid Challenges
- Astrana Health Reports Strong Revenue Growth in 2024
- Buy Recommendation for Astrana Health: Strong Financial Performance and Strategic Positioning Amid Temporary AI-Related Costs
Questions or Comments about the article? Write to editor@tipranks.com